Investment Analysts’ Weekly Ratings Updates for Regeneron Pharmaceuticals (REGN)

A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

• 4/8/2026 – Regeneron Pharmaceuticals had its price target lowered by Sanford C. Bernstein from $925.00 to $921.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $818.00 to $801.00. They now have a “buy” rating on the stock.
• 3/31/2026 – Regeneron Pharmaceuticals is now covered by Piper Sandler. They set an “overweight” rating and a $875.00 price target on the stock.
• 3/28/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/27/2026 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 3/8/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/6/2026 – Regeneron Pharmaceuticals is now covered by Barclays PLC. They set an “overweight” rating and a $923.00 price target on the stock.
• 3/2/2026 – Regeneron Pharmaceuticals had its price target raised by Royal Bank Of Canada from $745.00 to $765.00. They now have a “sector perform” rating on the stock.
• 2/28/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/16/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/9/2026 – Regeneron Pharmaceuticals had its price target raised by Guggenheim from $865.00 to $975.00. They now have a “buy” rating on the stock.
• 2/8/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,774 shares of company stock worth $2,942,738 over the last 90 days. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.